Outlook on the Nutraceuticals Sector for 2024-2025

We sought insights from industry experts deeply versed in market dynamics to discuss significant trends and developments in business, regulation, science, and the marketplace that the industry should focus on in the upcoming year. Their insights span a range of issues, including state regulations, global supply chain strategies, women’s health, and more.

Michael McGuffin, President of the American Herbal Products Association (AHPA), noted that 2024 brought considerable external pressure on the industry from both state and federal critics who often confuse safe, legal dietary supplements with illegal products. He emphasized the importance of industry unity in leveraging opportunities with the new government to highlight the unique health benefits of dietary supplements. AHPA plans to promote new legislative language to empower the FDA to crack down on illegal products masquerading as safe supplements.

Duffy MacKay, Senior VP of Dietary Supplements at the Consumer Healthcare Products Association (CHPA), reflected on the FDA’s ongoing challenges with products marketed as dietary supplements that contain active drug ingredients. He recounted significant regulatory actions, including a 2015 investigation by the New York State Attorney General into fraudulent supplements, which led to increased retail regulation.

Steve Mister, President and CEO of the Council for Responsible Nutrition (CRN), discussed the Dietary Supplement Health and Education Act (DSHEA), emphasizing the need for technical updates to keep pace with the industry’s growth without overhauling the foundational law. He highlighted the importance of pragmatic policy changes and industry unity in advocacy efforts.

Karen Howard, CEO and Executive Director of the Organic & Natural Health Association, outlined their focus on regulatory integrity, market access, and scientific innovation. She stressed the importance of improved testing methods and transparency in product ingredients, particularly those derived from synthetic biology.

Loren Israelsen, President of the United Natural Products Alliance (UNPA), discussed the significant changes expected in 2024, including potential impacts from political shifts and the nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services. He also highlighted the Supreme Court’s decision to end the Chevron Doctrine, which could reshape regulatory deference.

Jim Emme, CEO of NOW Health Group, reported strong growth in 2024, both domestically and internationally. He discussed challenges in the supply chain and regulatory environment, emphasizing the need for continued vigilance in product quality and consumer safety.

Karen E. Todd, Vice President of Global Brand Marketing at Kyowa Hakko USA, highlighted the shift in consumer preference towards scientifically supported branded ingredients over generics, noting the importance of transparency and scientific validation in consumer choices.

Shaheen Majeed, Global CEO & Managing Director of Sabinsa Corporation, discussed the complexities of pesticide testing in global markets and the importance of diversity in clinical research to address regional health needs and ensure comprehensive safety and efficacy studies.

These insights collectively underscore the dynamic nature of the dietary supplement industry and the critical need for proactive engagement, regulatory vigilance, and continuous innovation to navigate the challenges and opportunities ahead.